Literature DB >> 22617615

ACOG practice bulletin no. 127: Management of preterm labor.

.   

Abstract

Preterm birth is the leading cause of neonatal mortality and the most common reason for antenatal hospitalization(1–4). In the United States, approximately 12% of all live births occur before term, and preterm labor preceded approximately 50% of these preterm births (5, 6). Although the causes of preterm labor are not well understood, the burden of preterm births is clear—preterm births account for approximately 70% of neonatal deaths and 36% of infant deaths as well as 25–50% of cases of long-term neurologic impairment in children (7–9). A 2006 report from the Institute of Medicine estimated the annual cost of preterm birth in the United States to be $26.2 billion or more than$51,000 per premature infant (10). However, identifying women who will give birth preterm is an inexact process.The purpose of this document is to present the various methods proposed to manage preterm labor and to review the evidence for the roles of these methods in clinical practice. Identification and management of risk factors for preterm labor are not addressed in this document.

Entities:  

Mesh:

Year:  2012        PMID: 22617615     DOI: 10.1097/AOG.0b013e31825af2f0

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  48 in total

1.  Stability of developmental status and risk of impairment at 24 and 36 months in late preterm infants.

Authors:  Hooman Mirzakhani; Rachel S Kelly; Aishwarya P Yadama; Su H Chu; Jessica A Lasky-Su; Augusto A Litonjua; Scott T Weiss
Journal:  Infant Behav Dev       Date:  2020-06-26

Review 2.  A Cross-Species Analysis of Animal Models for the Investigation of Preterm Birth Mechanisms.

Authors:  Brian W Nielsen; Elizabeth A Bonney; Bradley D Pearce; Leah Rae Donahue; Indra Neil Sarkar
Journal:  Reprod Sci       Date:  2015-09-16       Impact factor: 3.060

3.  Effect of Gastric Fluid Volume on the In Vitro Dissolution and In Vivo Absorption of BCS Class II Drugs: a Case Study with Nifedipine.

Authors:  Ahmed M Nader; Sara K Quinney; Hala M Fadda; David R Foster
Journal:  AAPS J       Date:  2016-04-22       Impact factor: 4.009

Review 4.  Evidence-based practice in Malaysia: where are we and what more can be done?

Authors:  Cl Teng
Journal:  Malays Fam Physician       Date:  2013-08-31

5.  Treatment of spontaneous preterm labour with retosiban: a phase 2 proof-of-concept study.

Authors:  Steven Thornton; Hugh Miller; Guillermo Valenzuela; Jerry Snidow; Brendt Stier; Michael J Fossler; Timothy H Montague; Marcy Powell; Kathleen J Beach
Journal:  Br J Clin Pharmacol       Date:  2015-06-01       Impact factor: 4.335

Review 6.  Pharmacogenetics and individualizing drug treatment during pregnancy.

Authors:  David M Haas
Journal:  Pharmacogenomics       Date:  2014-01       Impact factor: 2.533

Review 7.  Public Health Implications of Very Preterm Birth.

Authors:  Wanda D Barfield
Journal:  Clin Perinatol       Date:  2018-09       Impact factor: 3.430

8.  The Impact of Maternal Body Mass Index and Gestational Age on the Detection of Uterine Contractions by Tocodynamometry: A Retrospective Study.

Authors:  A Aina-Mumuney; K Hwang; N Sunwoo; I Burd; K Blakemore
Journal:  Reprod Sci       Date:  2015-10-22       Impact factor: 3.060

9.  Placental origins of adverse pregnancy outcomes: potential molecular targets: an Executive Workshop Summary of the Eunice Kennedy Shriver National Institute of Child Health and Human Development.

Authors:  John V Ilekis; Ekaterini Tsilou; Susan Fisher; Vikki M Abrahams; Michael J Soares; James C Cross; Stacy Zamudio; Nicholas P Illsley; Leslie Myatt; Christine Colvis; Maged M Costantine; David M Haas; Yoel Sadovsky; Carl Weiner; Erik Rytting; Gene Bidwell
Journal:  Am J Obstet Gynecol       Date:  2016-03-10       Impact factor: 8.661

Review 10.  The prevention, diagnosis and treatment of premature labor.

Authors:  Ekkehard Schleußner
Journal:  Dtsch Arztebl Int       Date:  2013-03-29       Impact factor: 5.594

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.